BAY 41-2272 is a soluble guanylate cyclases (sGC) activator.
Target: guanylate cyclase
BAY 41-2272 is a recently introduced novel orally available agent that directly stimulates soluble guanylate cyclase (sGC) and sensitizes it to its physiological stimulator, nitric oxide. BAY 41-2272 is a promising new therapeutic agent that goes beyond current therapeutic agents. BAY 41-2272 acts as an arterial vasodilator, resulting in a reduction of MAP and pulmonary artery pressure and a decrease in SVR and renal vascular resistance. BAY 41-2272 reduces pulmonary capillary wedge pressure in the absence of a decrease in right atrial pressure. [2]
分子式
C20H17FN6
分子量
360.39
CAS号
256376-24-6
运输条件
Room temperature in continental US; may vary elsewhere.